<DOC>
	<DOCNO>NCT00040573</DOCNO>
	<brief_summary>This drug develop treat type brain cancer , glioma . This study design determine safe well tolerate dose . Patients must prior treatment glioma eligible removal recur tumor .</brief_summary>
	<brief_title>Safety Tolerability Study 131I-TM-601 Treat Adult Patients With Recurrent Glioma .</brief_title>
	<detailed_description>This open label single-dose study conduct 18 evaluable patient recurrent high-grade glioma . Patient undergone debulking surgery ventricular access device placement tumor cavity administration 131I-TM-601 . High-grade glioma include glioblastoma multiforme , anaplastic astrocytoma , anaplastic oligo-astrocytoma gliosarcoma . The amount 131I remain constant . Three dose TM-601 administer use dose escalate scheme .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Patient must give informed consent Patient must histologically confirm supratentorial malignant glioma Patients must recover toxicity prior therapy Patients must eligble resection recurrent tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Brain neoplasm</keyword>
	<keyword>Clinical trial , phase I/II</keyword>
</DOC>